Exagen Inc. $XGN Shares Purchased by Sei Investments Co.

Sei Investments Co. boosted its position in Exagen Inc. (NASDAQ:XGN) by 107.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 244,240 shares of the company’s stock after buying an additional 126,235 shares during the period. Sei Investments Co. owned approximately 1.01% of Exagen worth $733,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Truvestments Capital LLC lifted its stake in shares of Exagen by 109.5% in the 4th quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock worth $38,000 after acquiring an additional 3,225 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Exagen in the first quarter valued at about $25,000. Larson Financial Group LLC acquired a new position in shares of Exagen during the third quarter worth about $105,000. Persistent Asset Partners Ltd acquired a new position in shares of Exagen during the fourth quarter worth about $80,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Exagen during the fourth quarter worth about $82,000. 75.25% of the stock is owned by institutional investors and hedge funds.

Exagen Price Performance

Exagen stock opened at $6.58 on Friday. The stock has a market capitalization of $159.43 million, a P/E ratio of -8.12 and a beta of 2.05. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.18 and a quick ratio of 3.18. Exagen Inc. has a 12-month low of $2.59 and a 12-month high of $12.23. The firm’s 50-day moving average is $4.85 and its two-hundred day moving average is $3.94.

Exagen (NASDAQ:XGN) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. Exagen had a negative return on equity of 104.46% and a negative net margin of 26.61%.The company had revenue of $19.94 million for the quarter, compared to analyst estimates of $17.80 million. Equities analysts predict that Exagen Inc. will post -0.67 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on XGN. BTIG Research lifted their price objective on Exagen from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Roth Capital initiated coverage on Exagen in a research note on Wednesday, June 24th. They set a “buy” rating and a $8.00 target price for the company. B. Riley Financial reissued a “buy” rating and issued a $12.00 price target (up from $8.00) on shares of Exagen in a report on Wednesday, August 5th. Wall Street Zen upgraded Exagen from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group dropped their price objective on Exagen from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Exagen has an average rating of “Moderate Buy” and an average target price of $9.62.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.